Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Verastem, Inc.
Sponsor:
Information provided by (Responsible Party):
Verastem, Inc.
ClinicalTrials.gov Identifier:
NCT01991938
First received: November 18, 2013
Last updated: April 25, 2014
Last verified: April 2014

November 18, 2013
April 25, 2014
November 2013
October 2015   (final data collection date for primary outcome measure)
  • Assess the safety and tolerability of VS-5584 in subjects with advanced non-hematologic malignancies or lymphoma [ Time Frame: From start of treatment to end of treatment, an expected average of 6 weeks ] [ Designated as safety issue: Yes ]
    Serious Adverse events, Adverse events and their frequency, duration and severity, physical examination, laboratory parameters, vital signs and ECGs as determined based on CTCAE (Common Toxicity Criteria for Adverse Effects) V4.03. A Safety Monitoring Committee will review safety information.
  • Determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) and schedule of VS-5584 administered to subjects with advanced non-hematologic malignancies or lymphoma [ Time Frame: From start of treatment to end of Cycle 1 (21 day cycles) ] [ Designated as safety issue: Yes ]
    The RP2D will be determined based on the MTD of VS-5584 as determined by number of participants with dose limiting toxicities related to VS-5584. Observations related to pharmacokinetics, pharmacodynamics, and any VS-5584 related toxicities may be included in the rationale supporting the RP2D and schedule and will not exceed the MTD.
Same as current
Complete list of historical versions of study NCT01991938 on ClinicalTrials.gov Archive Site
Assess the pharmacokinetics of VS-5584 [ Time Frame: Time points on Day 1, 2, 3, 17, 18 ] [ Designated as safety issue: No ]
PK (pharmacokinetics) parameters, including but not limited to plasma concentration, clearance, AUC (Area Under Curve, 0-24 and 0-t), Cmax, Tmax, and T1/2
Same as current
  • Evaluate the efficacy of VS-5584 [ Time Frame: Every 6 weeks to end of treatment, expected average of 6 weeks ] [ Designated as safety issue: No ]
    Response rate and progression-free survival as determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 or by the Revised Response Criteria for Malignant Lymphoma
  • Evaluate the time to new lesion [ Time Frame: Expected average of 6 weeks from start of treatment to end of treatment ] [ Designated as safety issue: No ]
  • Evaluate duration of response to VS-5584 compared with duration of response to prior therapy [ Time Frame: Expected average of 6 weeks from start of treatment to end of treatment ] [ Designated as safety issue: No ]
  • Examine the pharmacodynamic effect of VS-5584 on target proteins in platelet rich plasma and tumor biopsies [ Time Frame: Platelet rich plasma time points: Day 1, 2, 8, 17; Tumor biopsies time points: Screening, Day 22, and at the time of progression ] [ Designated as safety issue: No ]
    Pharmacodynamic and predictive response biomarkers intended to demonstrate inhibition of the molecular target and determination of the mechanism of action will be assessed in archival tissue and tumor biopsies and platelet rich plasma samples.
  • Examine if tumor genetic alterations and/or plasma biomarkers correlate with response to VS-5584 therapy [ Time Frame: start of treatment to end of treatment, an expected average of 6 weeks ] [ Designated as safety issue: No ]
    Tumor genetic alterations and/or plasma biomarkers compared with response to VS-5584, as determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 or Revised Response Criteria for Malignant Lymphoma
Same as current
 
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

This is a Phase I, open-label, multicenter, dose-escalation trial of VS-5584, a PI3K/mTOR kinase inhibitor, in subjects with advanced non-hematologic malignancies or lymphoma. This clinical study is comprised of 2 sequential parts: Part 1 (Dose Escalation) and Part 2 (Expansion). The purpose of this study is to evaluate the safety (including the recommended Phase II dose), pharmacokinetics (the amount of VS-5584 in subject's blood) and the anti-cancer activity of VS-5584. Biomarkers (genes or proteins that may predict or show how subject's body may respond to VS-5584) will also be assessed in archival tumor tissue, tumor biopsies (in consenting subjects), and blood samples.

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Non Hematologic Cancers
  • Metastatic Cancer
  • Lymphoma
Drug: VS-5584
Experimental: VS-5584
Oral VS-5584 administered once daily on Day 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each cycle
Intervention: Drug: VS-5584
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
62
Not Provided
October 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Able to provide signed and dated informed consent prior to initiation of any study procedures.
  2. Age ≥ 18 years.
  3. Subjects must have a histopathologically confirmed diagnosis of an advanced non-hematologic malignancy or lymphoma.
  4. Subjects must have no alternate therapy of proven benefit or have refused standard therapy.
  5. All clinically significant toxicities from prior chemotherapy must be ≤ Grade 1.
  6. ECOG performance status of 0 or 1, measured at screening and immediately before the start of treatment.
  7. Predicted life expectancy of ≥ 3 months.
  8. Fasting blood glucose of ≤ 140 mg/dL (7.8 mmol/L).
  9. Adequate renal function [creatinine ≤ 1.5x ULN (upper limit of normal)] or GFR of ≥ 50mL/min.
  10. Adequate hepatic function (total bilirubin ≤ 1.5x ULN for the institution; AST [aspartate transaminase] and ALT [alanine transaminase] ≤ 3x ULN).
  11. Adequate bone marrow function (hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x10^9 cells/L; absolute neutrophil count ≥ 1.5x10^9 cells/L).
  12. Corrected QT interval (QTc) < 470 ms (as calculated by the Fridericia correction formula).
  13. Negative pregnancy test for women of child-bearing potential.
  14. Men and women of child bearing potential must agree to use adequate birth control throughout their participation in the study and for 60 days following the last study treatment.
  15. Willing and able to participate in the trial and comply with all trial requirements.
  16. Subjects must have archival tumor tissue available for mutational analysis. A study specific biopsy can be performed if archival tissue is not available.

Exclusion Criteria:

  1. Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication.
  2. Uncontrolled or severe concurrent medical condition (including uncontrolled brain metastases). Stable brain metastases either treated or being treated with a stable dose of steroids/ anticonvulsants, with no dose change within 28 days prior to the first dose of study drug, will be allowed.
  3. History of upper gastrointestinal bleeding, ulceration, or perforation within 12 months prior to the first dose of study drug.
  4. Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug.
  5. Subjects with known infection with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS) (testing not required).
  6. Subjects with known active Hepatitis A, B or C (testing not required).
  7. Subjects being actively treated for a secondary malignancy.
  8. Cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy with the exception of LHRH agonists for prostate cancer, biologic or immunotherapy, etc.) within 21 days of the first dose of study drug or 5 half-lives, whichever is shorter. Palliative radiotherapy is allowed prior to initiating treatment if associated toxicity resolved to ≤ Grade 1.
  9. Subjects currently taking medications known to be strong CYP3A4 inhibitors.
  10. Major surgery within 28 days prior to the first dose of study drug.
  11. Subjects with acute or chronic pancreatitis.
  12. Subjects with diabetes mellitus requiring insulin treatment or subjects with a HbA1C > 7.
  13. Use of an investigational drug within 28 days or 5 half-lives (whichever is shorter) prior to the first dose of study drug. A minimum of 14 days between termination of the investigational drug and administration of the study treatment is required. In addition, any drug-related toxicity except alopecia should have recovered to grade 1 or less.
  14. Women who are pregnant or breastfeeding.
  15. Any evidence of serious active infections.
  16. Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis.
  17. Uncontrolled intercurrent illness including symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Both
18 Years and older
No
Contact: Mitchell Keegan, Ph.D. 617-252-9320 mkeegan@verastem.com
United States,   United Kingdom
 
NCT01991938
VS-5584-101
No
Verastem, Inc.
Verastem, Inc.
Not Provided
Study Director: Mitchell Keegan, Ph.D. Verastem, Inc.
Verastem, Inc.
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP